- Tocilizumab, marketed as Actemra, is taken by patients with rheumatoid arthritis
- It reduces inflammation, which is considered a complication of COVID-19
- It causes lung damage and organ failure, eventually death in most cases
- Chinese doctors gave it to 20 patients during the peak of the countries epidemic
- Nineteen were discharged within 14 days despite being critically ill
- Actemra has now been approved for use in China and for trials in the US
Tuesday 5 May 2020
arthritis drug being used to treat coronavirus patients in China helped to cure 95 PER CENT of critically ill patients, scientists claim
Daily Mail
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment